Premium
Effect of sulphinpyrazone on human platelet aggregation, 5‐ hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.
Author(s) -
Nunn B,
James FJ
Publication year - 1980
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1980.tb04833.x
Subject(s) - ex vivo , sulfinpyrazone , naproxen , platelet , chemistry , pharmacology , platelet adhesiveness , in vivo , platelet aggregation , in vitro , biochemistry , medicine , immunology , biology , alternative medicine , microbiology and biotechnology , pathology
1 The effects of single doses of naproxen and sulphinpyrazone and of 4 and 8 days treatment with sulphinpyrazone on human platelet responsiveness were compared. 2 A single dose of sulphinpyrazone had no effect whereas a single dose of naproxen caused a five‐fold depression in responsiveness to collagen. 3 Repeated administration of sulphinpyrazone led to a weak and equivocal inhibitory effect on collagen‐induced aggregation, second phase aggregation in response to ADP and adhesion to collagen. There was no effect on ADP‐induced first phase aggregation, adrenaline‐induced second phase aggregation or platelet retention in glass bead columns. 4 It is concluded that the anti‐aggregant activity of sulphinpyrazone is too weak to be a major factor in its reported effect on the incidence of cardiac death.